Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

OBJECTIVE: To evaluate efficacy and safety of guselkumab, an anti-interleukin-23p19-subunit antibody, in patients with psoriatic arthritis (PsA) with prior inadequate response (IR) to tumour necrosis factor inhibitors (TNFi). METHODS: Adults with active PsA (≥3 swollen and ≥3 tender joints) who disc...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C, Gossec, Laure, Theander, Elke, Bergmans, Paul, Neuhold, Marlies, Karyekar, Chetan S, Shawi, May, Noël, Wim, Schett, Georg, McInnes, Iain B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862038/
https://www.ncbi.nlm.nih.gov/pubmed/34819273
http://dx.doi.org/10.1136/annrheumdis-2021-220991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862038/
https://www.ncbi.nlm.nih.gov/pubmed/34819273
http://dx.doi.org/10.1136/annrheumdis-2021-220991

Ejemplares similares